中文 English

PlasAim® Lung Cancer Non-invasive Assay

Detection method

The highly sensitive library preparation technology and efficient target enrichment method used in this assay, compared to PCR and Sanger sequencing methods, is able to simultaneously detect mutations in the full coding sequence of multiple genes.

Test significance

This assay provides guidance for targeted treatment related to mutations, insertions/deletions, amplifications, and fusions in non-small cell lung cancer.

Product advantage

- Comprehensive: Detection of all exons and variants of 12 genes using ddCAP technology, simultaneous detection of SNVs, indels, CNVs and fusions.

- Precise: Accurately locates the gene sites of targeted drugs for lung cancer and meets the requirements of clinical diagnosis and treatment.

- Quality: Sequencing depth of at least 20,000X with 0.01% analytical sensitivity.

Detection of genes

Tumor genes(12)

  • ALK
  • BRAF
  • ERBB2
  • EGFR
  • FGFR1
  • MET
  • KRAS
  • NRAS
  • PIK3CA
  • TP53
  • RET
  • ROS1

Applicable to cancer patients

- Guide targeted drug therapy for advanced lung cancer patients whose tissue samples are not available. 

- Explore the cause and mechanism of drug resistance and adjust the treatment options for lung cancer patients with disease progression. 

- Patients requiring continuous monitoring, where real-time dynamic monitoring of curative effects and disease progression is carried out during targeted drug therapy.

Test procedure

*Product is for research use only.